Literature DB >> 10682712

Effect of acute and chronic administration of 1,2,3,4-tetrahydroisoquinoline on muscle tone, metabolism of dopamine in the striatum and tyrosine hydroxylase immunocytochemistry in the substantia nigra, in rats.

E Lorenc-Koci1, M Smiałowska, L Antkiewicz-Michaluk, K Gołembiowska, M Bajkowska, S Wolfarth.   

Abstract

The effects of acute and chronic administration of 1,2,3,4-tetrahydroisoquinoline, an endogenous substance suspected of producing parkinsonism in humans, on the muscle tone and metabolism of dopamine in the striatum, and on the number of tyrosine hydroxylase-immunoreactive cells in the substantia nigra were investigated in rats. Muscle tone was examined using a combined mechanomyographic and electromyographic method which measured simultaneously the muscle resistance of the rat's hind foot to passive extension and flexion in the ankle joint and electromyographic activity of the antagonistic muscles of that joint: gastrocnemius and tibialis anterior. 1,2,3,4-Tetrahydroisoquinoline administered at doses of 50 and 100 mg/kg intraperitoneally for 19 days increased muscle resistance 1 h after the first injection (acute treatment), 1 h after the last injection (chronic treatment) and three days after compound withdrawal. Rigidity observed on the third day of 1,2,3,4-tetrahydroisoquinoline withdrawal was accompanied by an increased tonic (resting) electromyographic activity of the gastrocnemius and tibialis anterior muscles. At the same time, a significant reduction in the number of tyrosine hydroxylase-immunoreactive neurons in the substantia nigra and a decrease in the dopamine level in the striatum were also found. A declining number of tyrosine hydroxylase-immunoreactive neurons in the whole substantia nigra showed a significant negative correlation with the enhanced muscle resistance, as well as with the tonic electromyographic activity recorded at rest, i.e. before the start of movements, from the gastrocnemius and tibialis anterior muscles. Our results suggest that 1,2,3,4-tetrahydroisoquinoline may be one of the endogenous substances involved in the progress of Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10682712     DOI: 10.1016/s0306-4522(99)00511-4

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  10 in total

1.  A novel compound PTIQ protects the nigral dopaminergic neurones in an animal model of Parkinson's disease induced by MPTP.

Authors:  Hyo Jin Son; Ji Ae Lee; Nari Shin; Ji Hyun Choi; Jai Woong Seo; Dae Yoon Chi; Cheol Soon Lee; Eun-Mee Kim; Han Choe; Onyou Hwang
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

2.  Alterations in the proportions of skeletal muscle proteins following a unilateral lesion to the substantia nigra pars compacta of rats.

Authors:  A Sliwinski; D Stanic; D I Finkelstein; M Ilic; J M West; P C Dooley
Journal:  J Muscle Res Cell Motil       Date:  2005-07-01       Impact factor: 2.698

3.  Reduced metabotropic glutamate receptor 5 in the Flinders Sensitive Line of rats, an animal model of depression: an autoradiographic study.

Authors:  Tomislav Kovačević; Ivan Skelin; Luciano Minuzzi; Pedro Rosa-Neto; Mirko Diksic
Journal:  Brain Res Bull       Date:  2012-01-31       Impact factor: 4.077

4.  An endogenous neuroprotectant substance, 1-methyl-1,2,3,4-tetrahydroisoquinoline (1MeTIQ), prevents the behavioral and neurochemical effects of cocaine reinstatement in drug-dependent rats.

Authors:  L Antkiewicz-Michaluk; M Filip; J Michaluk; I Romańska; E Przegaliński; J Vetulani
Journal:  J Neural Transm (Vienna)       Date:  2006-08-10       Impact factor: 3.575

Review 5.  A possible physiological role for cerebral tetrahydroisoquinolines.

Authors:  Jerzy Vetulani; Lucyna Antkiewicz-Michaluk; Irena Nalepa; Mario Sansone
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.911

6.  Both stereoselective (R)- and (S)-1-Methyl-1,2,3,4-tetrahydroisoquinoline enantiomers protect striatal terminals against rotenone-induced suppression of dopamine release.

Authors:  Lucyna Antkiewicz-Michaluk; Agnieszka Wąsik; Irena Romańska; Andrzej Bojarski; Jerzy Michaluk
Journal:  Neurotox Res       Date:  2010-11-11       Impact factor: 3.911

7.  Chronic salsolinol administration prevents the behavioral and neurochemical effects of L-DOPA in rats.

Authors:  Agnieszka Wąsik; Irena Romańska; Jerzy Michaluk; Lucyna Antkiewicz-Michaluk
Journal:  Neurotox Res       Date:  2015-02-25       Impact factor: 3.911

8.  Salsolinol, an endogenous compound triggers a two-phase opposing action in the central nervous system.

Authors:  Edyta Możdżeń; Małgorzata Kajta; Agnieszka Wąsik; Tomasz Lenda; Lucyna Antkiewicz-Michaluk
Journal:  Neurotox Res       Date:  2014-12-24       Impact factor: 3.911

Review 9.  Brain sites of movement disorder: genetic and environmental agents in neurodevelopmental perturbations.

Authors:  T Palomo; R J Beninger; R M Kostrzewa; T Archer
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.978

10.  Crystal structure of 2-methyl-1,2,3,4-tetra-hydro-iso-quinoline trihydrate.

Authors:  Felix Langenohl; Felix Otte; Carsten Strohmann
Journal:  Acta Crystallogr E Crystallogr Commun       Date:  2020-02-06
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.